Plain-English translation of NCT06319846 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a medication called to see if it can prevent a second stroke in people who have just experienced a minor stroke or a warning sign (TIA) and have a narrowed artery inside the brain. works by making blood less likely to clot. Researchers want to know whether giving this medication within 24 hours of a stroke can reduce the chance of another stroke happening within three months.
People with narrowed arteries inside the brain are at high risk of having another stroke soon after their first one. Current treatments don't always prevent these repeat strokes, so doctors are testing whether this medication can offer better protection.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will receive either the study medication or a placebo (inactive saline) through an IV within 24 hours of your stroke symptoms. The medication or placebo starts with a 30-minute infusion, then continues for 48 hours. You will be followed up at 3 months to see whether you have had another stroke and to check for any bleeding or safety concerns.
AI-generated summary from trial data · Jun 1, 2026 · Not medical advice
China